Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Coiffier, B., Thiéblemont, C., Neste, É. V. D., Lepeu, G., Plantier, I., Castaigné, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276246 · Cited by 1,539

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Rummel, M., Niederle, N., Maschmeyer, G., Banat, G.-A., von Grünhagen, U., Losem, C. J., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,512

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,317

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Salles, G., Seymour, J. F., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,075

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

Marcus, R. E. (2004) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 972

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu364 · Cited by 177

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

Shpilberg, O., & Jackisch, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.371 · Cited by 138

Designing a Patient Preference Study on Subcutaneous Medical Devices: Incorporating Health Authority Scientific Advice and Patient Perspectives

Picci, M., Cook, N. S., Jones, B. C., Zhou, M., Berlin, C., Sturchler, C., MARTINEZ, C., Baena, I. G., Ziegler, L., Gaunt, H., et al. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-024-00725-3 · Cited by 5

Safety and Efficacy of the First Subcutaneous ICI , Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real‐World Study

Dou, Z., Wang, L., Rui, M., Yang, Y., Zhou, Y., Zhang, J., Zhao, Q., Wang, M., Wang, H., Zhang, X., et al. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70101 · Cited by 5

Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study

Sazatornil, M. R. A., Arenaza, A., Bayo, J. L., Mata, J. G., de Castro, J. M. G., León, J., Letéllez-Fernández, J., Reguero, V., Chamorro, C. M., & Salar, A. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06277-8 · Cited by 5

A review of use errors reported in human factor validation studies of biological combination products

Patel, R. B., Mehta, M., Dahiya, M., & Jose, V. M. (2021) · Journal of Medical Engineering & Technology · doi:10.1080/03091902.2021.1936239 · Cited by 5

Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale

Dürig, J., Uhlig, J., Gerhardt, A., Ritter, M., Hapke, G., Heßling, J., Staib, P., Wolff, F., Krumm, K., & von Weikersthal, L. F. (2022) · Cancer Medicine · doi:10.1002/cam4.5160 · Cited by 5

Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next

Petrelli, F., Iaculli, A., Zambelli, A., Ghidini, M., Dottorini, L., & Tomasello, G. (2026) · JCO Oncology Practice · doi:10.1200/op-25-00955 · Cited by 4

Model‐Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation

Zhao, Y., Vezina, H. E., Hu, Z., Kondic, A. G., Zhu, L., & Roy, A. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70120 · Cited by 4

Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study

Lonardi, S., Lugowska, I. A., O’Donnell, A. E., Jackson, C., Latten-Jansen, L. M., North, R. T., Bahleda, R., Marcelo Garrido, S., Santoro, A., Chacon, M. R., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011918 · Cited by 4

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

Bartlett, N. L., Sehn, L. H., Assouline, S. E., Giri, P., Kuruvilla, J. G., Schuster, S. J., Yoon, S., Fay, K. C., Heß, G., Dreyling, M. H., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70225 · Cited by 4

A value assessment of patient-level outcomes and productivity loss for intravenous and subcutaneous lecanemab for patients with early Alzheimer’s disease

Ressa, R., Ettinger, J., Chowdhury, E., Graham, L., Ndirangu, K., Mancebo, J. Z., & Bodnar, C. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2025.2609499 · Cited by 4

Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indications

Song, G. K., Erman, M., Martinengo, G. L., Kocsis, J., Kunta, G., Wang, M., Yoshioka, H., Silva, C. D. M., & Lala, M. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115711 · Cited by 4

Subcutaneous rituximab—a meaningful advance in care

Assouline, S. E. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30079-0 · Cited by 3

Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center

Sánchez‐González, B., Torres, E., Ferraro, M. P., Calafell, M., Gale, C., Martínez, L., Sancho, E., Garcia, P., Gimeno, E., García‐Pallarols, F., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1349906 · Cited by 3

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases

Péterlin, P., Guillaume, T., Garnier, A., Bourgeois, A. L., Mahé, B., Dubruille, V., Blin, N., Gallas, P., Touzeau, C., Gastinne, T., et al. (2018) · Leukemia Research Reports · doi:10.1016/j.lrr.2018.01.002 · Cited by 3

Administration of nivolumab plus ipilimumab: Infusion of the fixed‐ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)

Menzies, A. M., Salman, P., Frontera, O. A., Pook, D. W., Hocking, C. M., Zakharia, Y., Gurney, H., Gedye, C. A., Goh, J. C. H., Telivala, B. P., et al. (2025) · Cancer · doi:10.1002/cncr.35962 · Cited by 2

Multidimensional impact of fixed-dose subcutaneous trastuzumab-pertuzumab on oncology workflow and patient time burden in a real-world study

Oshi, M., Nakayama, T., Ota, I., Sasamoto, M., Yamada, A., Narui, K., Takabe, K., & Endo, I. (2025) · Breast Cancer · doi:10.1007/s12282-025-01803-6 · Cited by 3

Saudi lymphoma group's clinical practice guidelines for diagnosis, management and follow-up of patients with various types of lymphoma during the Coronavirus Disease 2019 pandemic

Alzahrani, M. F., Al-Mansour, M. M., Apostolidis, J. P., Barefah, A., Dada, R., Alhejazi, A., Alayed, Y. M., Motabi, I., Radwi, M., & Alhashmi, H. (2020) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_457_20 · Cited by 2

Subcutaneous rituximab for autoimmune bullous diseases

Loughlin, C. R., & Iranzo, P. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20493 · Cited by 2

Clinical development of subcutaneous dosing alternatives to established intravenous formulations for monoclonal antibodies—pharmacokinetic-based bridging approach

Bittner, B., & Schmidt, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823741-0.00002-6 · Cited by 2

Investigation into the Acceptability of Moderate-to-Large Volume Subcutaneous Injections in Healthy Volunteers: Results from a Single-Center Randomized Controlled Study

Akinseye, C., Fiorini, A., Jarvis, E., Fry, M., Raza, A., Soleman, S., Igwe, S., & Palmer, M. (2024) · Medical Devices Evidence and Research · doi:10.2147/mder.s479507 · Cited by 4

Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial

Gao, Y., Zhang, L., Gao, S., Yang, Y., Zhang, Q., Zhang, H., He, P., Li, F., Jing, H., Grange, S., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2439525 · Cited by 2

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda

Menon, M. P., Ddungu, H., Mubiru, K. R., Adams, S. V., Asea, J., Namagembe, R., Namuli, P., Kambugu, J., Towlerton, A. M. H., Puronen, C. E., et al. (2025) · JCO Global Oncology · doi:10.1200/go-24-00489 · Cited by 2

Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies

Penkov, K., Bondarenko, I., Saenko, D. V., Kulyaba, Y., Guo, J., Gong, Y., Yamamoto, N., Hotko, Y., Boyko, V., Fadeeva, N., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241274592 · Cited by 1

Patient experience in healthcare interventions: PROM and PREM evaluation in patients with multiple sclerosis after switching administration route of natalizumab

Fernández-Cuerva, C., Alarcón, A. L., Lara, M. J. M., Alonso, A., Reyes-Garrido, V., Urbaneja, P., & Benavente, A. S.-G. (2025) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2024-004378 · Cited by 1

Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer

Majem, M., Chewaskulyong, B., Zvirbule, Z., Lee, K. H., Korbenfeld, E. P., Kołb-Sielecki, J., Sanchez, A. Y. C., Bustillos, A., Herráez-Baranda, L. A., Liu, X., et al. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00402-x · Cited by 1

Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma

Ocio, E. M., Parmar, G., Mateos, M., Leleu, X. P., Buck, T. T., Tan, C. R., Curry, N. C., Ling, S., Quach, H., Mai, E. K., et al. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2659263 · Cited by 2

The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study

Huang, T., Fan, Z., Wang, Y., Yan, X., Yang, H., Wang, S., Pang, D., Li, H. P., Wang, H., Geng, C., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02935-7 · Cited by 1

Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma

Blosser, N., Jupp, J., Yau, P., & Stewart, D. A. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00807-8 · Cited by 1

Modelo de impacto orçamentário do rituximabe subcutâneo comparado ao intravenoso no tratamento do linfoma não Hodgkin difuso de grandes células B, CD-20 positivo, no sistema de saúde suplementar brasileiro

Kashiura, D., Souza, P. V., dos Santos, H. P., Nardi, E., Sa, A., Santos, B., & Alves, M. (2018) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v10.n3.p255-61 · Cited by 1

B-Hücreli Non-Hodgkin Lenfoma Tanılı Hastalarda Subkutan Rituksimab Tedavi Sonuçlarının Değerlendirilmesi: Tek Merkez Deneyimi

Teke, H. Ü., YAMAN, F., Andıç, N., & Gündüz, E. (2022) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.1074211 · Cited by 1

Patient voice in clinical trial programs in industry

Regnante, J. M., Schrandt, S., Richie, N. A., Roberts, J. N., Yeoman, G., Brooke, N. J., Schneider, R. F., Murray, M. S., Sargeant, I., Metcalf, M. A., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817663-4.00026-x

Quality of life patients treated with rituximab intravenous versus subcutaneous in B-cell lymphomas: results from outpatient Hematooncology Clinic in Lodz

Witkowska, M., Witkowska, S., Klimczak, M., Frydecka, A., Witkowski, M., & Smolewski, P. (2021) · Oncoreview · doi:10.24292/01.or.1222550621

Boas Práticas na Administração do Rituximab: Revisão Integrativa da Literatura

Rodrigues, C. A., de Lima, M. T. C., & Domenico, E. B. L. D. (2022) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2022v68n3.2194

Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following AerosolizationviaMesh Nebulizer

Zaleskis, G., Talaikis, M., Characiejus, D., Urbonas, V., Bosas, P., Darinskas, A., ZIBUTYTE, L., SIMKUS, L., Survila, Ž., Juršėnaitė, J., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16251

Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis

Alexander, M., Jachno, K., Phillips, K., Seymour, J. F., Slavin, M. A., Cheung, A., Shen, V., Maarouf, D., Wolfe, R. S., & Lingaratnam, S. M. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231180875

Subcutaneous rituximab in indolent primary cutaneous B cell lymphoma: A case series of 5 patients with the evaluation of the medico economic impact

Fassanaro, C., Mortier, L., Carpentier, O., Arib, I., Dervaux, B., & Faiz, S. (2025) · Therapies · doi:10.1016/j.therap.2025.04.001

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Tomlins, E., Winter, H. R., Olsson-Brown, A. C., Robinson, J., Long, S., Sheppard, S., Harnett, C., Dulloo, S., & Pickering, S. J. (2025) · British Journal of Nursing · doi:10.12968/bjon.2025.34.sup10b.s4

Weekly Rapid Infusion Rituximab Treatment in Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia: Is It Safe and Effective?

Duran, M., & Beğendi, N. K. (2025) · Medical Records · doi:10.37990/medr.1658891

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Williams, J., Tomlins, E., Winter, H. R., Olsson-Brown, A. C., Robinson, J., Long, S., Sheppard, S., Harnett, C., Dulloo, S., & Pickering, S. J. (2025) · British Journal of Nursing · doi:10.12968/bjon.2025.34.sup10b.s1

Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US

Mulvey, E. C., Shafrin, J. T., Than, K., Muthukrishnan, S., Mutebi, A., Chhibber, A., Wang, A., Alshreef, A., Harb, D. E., Gonzalez, V., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2572784

From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching

Gaudio, M., Floreani, A., Schivardi, G., Alaimo, D., Basilico, V., Lorenzetti, I., Crepaldi, C., Tinterri, B., Panzardi, A., Strada, D., et al. (2025) · Tumori Journal · doi:10.1177/03008916251401048

Additional file 1 of Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study

Abad-Sazatornil, M. R., Arenaza, A., Bayo, J. L., Mata, J. G., Guinea De Castro, J. M., León, J., Letellez, J., Reguero, V., Martínez Chamorro, C., & Salar, A. (2021) · Figshare · doi:10.6084/m9.figshare.14391300

Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review

Schroer, J., Bröckelmann, P. J., Salek, S., Ionova, T., Laane, E., Olíva, E. N., Monsef, I., Skoetz, N., & Csenar, M. (2026) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-026-00999-1 · Cited by 1

Quality of life and effectiveness of vutrisiran as treatment for hereditary transthyretin amyloidosis

Villanueva, J. C., & Sacristán, A. A. G. (2026) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.12.010

Synthesis, evaluation and administration of water-soluble polymer prodrugs for the subcutaneous administration of vesicant anticancer drugs

Tomasini, L. (2023) · doi:10.70675/20a14da4z235cz4110z85afza39557c573bb

[Artículo traducido] Calidad de vida y efectividad de vutrisiran como tratamiento para la amiloidosis hereditaria por transtirretina

Villanueva, J. C., & Sacristán, A. A. G. (2026) · Farmacia Hospitalaria · doi:10.1016/j.farma.2026.03.007

Health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma – Canadian perspective

Guinan, K., Pelletier, M., Ham, M., Tankala, D., Roc, N. P., Klil-Drori, A. J., Wang, A., Fleury, I., Macdonald, D. A., Lachaîne, J., et al. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0187

Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study

Casarini, I., Kowalski, D. M., Caglevic, C., Yayla, Ş. B., Sümbül, A. T., Weber, P. E. Y., Castilla, A. Y., Bylicki, O., Takagi, T., McQuarrie, K., et al. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01248

Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer

Liu, X., Guan, Y., Liu, Y., Tian, Y., Abdrashitov, R., Niu, Z., Lin, X., Ye, X., Wang, Y., Sahasranaman, S., et al. (2026) · Clinical and Translational Science · doi:10.1111/cts.70649

Transitioning Therapeutic Antibodies in Oncology from Intravenous to Hyaluronidase-Facilitated Subcutaneous Administration

Xu, S. X. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01669-7

Analyzing the impact of subcutaneous injection needle, device, and administration characteristics on patient pain, anxiety, and safety: a systematic literature review

Desai, M. G., Candiotti, K., Pinkhasov, A., Hunter, R. B., Chopra, H., Gorski, L., & Shenoy, S. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2719057

Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma

Parmar, G., Capra, M., Hungria, V., Seguro, F. S., Dimopoulos, M. A., Delimpasi, S., Špička, I., Minařík, J., Marques, H., Pour, L., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.08.019

From haematology to rheumatology: intravenous-to-subcutaneous rituximab transition in Sjögren’s disease-associated cryoglobulinaemic vasculitis

Mai, Y.-F., Tsai, C., & Chen, W. (2026) · Lara D. Veeken · doi:10.1093/rheumatology/keag508

Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

Bobin, A., Durocher, L., Touzeau, C., Branche, N., Perrot, A., Dib, M., Blade, J., Chalopin, T., Montes, L., Gay, J., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01634-4

Prefmab: Final Analysis of Patient Preference for Subcutaneous Versus Intravenous Rituximab in Previously Untreated CD20+ Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Rummel, M., Kim, T. M., Plenteda, C., Capochiani, E., Mendoza, M., Smith, R. B. W., Osborne, S., & Grigg, A. (2015) · Blood · doi:10.1182/blood.v126.23.3972.3972 · Cited by 5

Prefmab: Final Analysis Of Patient Satisfaction With Subcutaneous Versus Intravenous Rituximab In Previously Untreated Cd20+ Diffuse Large B-Cell Lymphoma Or Follicular Lymphoma

Rummel, M., Kim, T., Plenteda, C., Capochiani, E., Mendoza, M., Smith, R., Osborne, S., & Grigg, A. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.1237 · Cited by 2

NHL Patients and Nurses in the US Prefer Subcutaneous Rituximab Injection Versus Intravenous Rituximab Infusion: A Real-World Study

Gandhi, M. D., Shapouri, S., Ravelo, A., Sudharshan, L., Beeks, A., & Dawson, K. L. (2020) · Blood · doi:10.1182/blood-2020-136543 · Cited by 4

Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute

Rule, S. A., Briones, J., Smith, R., Theodore, O. C., Ngoh, C. A., Osborne, S., Capochiani, E., & Rummel, M. (2014) · Value in Health · doi:10.1016/j.jval.2014.08.1719 · Cited by 16

Subcutaneous versus intravenous rituximab administration in first-line diffuse large B-cell lymphoma and follicular lymphona: Prefmab study of patient preference and satisfaction in 19 countries

Rummel, M., Kim, T. M., Jensen, P., Pereira, W. V., Re, F. D., Mendoza, M. B., Osborne, S., Smith, R. L., & Grigg, A. (2016) · VBN Forskningsportal (Aalborg Universitet)